<DOC>
	<DOCNO>NCT01835236</DOCNO>
	<brief_summary>In HER2-positive metastatic breast cancer , trastuzumab base treatment standard care long contraindication trastuzumab . Frequently , trastuzumab combine taxanes first-line setting . However , since therapy trastuzumab active even absence chemotherapy HER2-positive MBC , optimal treatment strategy either combination sequence chemotherapy still debate . This randomized phase II trial study new strategy treatment metastatic breast cancer HER2-positive . First-line treatment consist trastuzumab pertuzumab , treatment without chemotherapy . In case disease progression , chemotherapy T-DM1 perform second-line treatment . Third-line line therapy perform accord physician 's discretion . If new therapeutic strategy effective well tolerate conventional strategy , would mean serious breakthrough treatment HER2-positive metastatic breast cancer .</brief_summary>
	<brief_title>Trastuzumab &amp; Pertuzumab Followed T-DM1 MBC</brief_title>
	<detailed_description>OBJECTIVES : Primary -To evaluate efficacy term overall survival ( OS ) 24 month chemotherapy-free dual HER2-inhibition trastuzumab pertuzumab ( first-line ) follow T-DM1 ( second-line ) chemotherapy-containing dual HER2-inhibition trastuzumab pertuzumab ( first-line ) follow T-DM1 ( second-line ) patient HER2-positive metastatic breast cancer . Secondary - To evaluate efficacy parameter - To evaluate safety tolerability profile two treatment strategy - To evaluate Quality Life ( QoL ) - To learn patient treated trial treatment OUTLINE : This multicenter study . Patients stratify accord hormone receptor status ( positive v negative ) , prior trastuzumab ( never &gt; 12 month vs ≤12 month last infusion ) , visceral metastasis ( present v absent ) site . Patients randomize 1 2 treatment arm .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>SELECTION OF PATIENTS ( MOST IMPORTANT CRITERIA ) Inclusion criterion firstline therapy • Histologically confirm breast cancer distant metastasis Note : 1 . A biopsy primary tumor metastasis use diagnosis . 2 . Patients nonmeasurable lesion eligible . 3 . Patients inoperable , locally advanced breast cancer lymph node metastases ipsilateral locoregional ( axillary , infraclavicular , parasternal ) distant metastasis eligible . 4 . Patients bone metastasis without bone target therapy ( bisphosphonates , denosumab ) eligible . 5 . Patients denovo Stage IV disease eligible . HER2positive tumor accord central pathology test HER2 Note : 1 . A formalinfixed paraffinembedded ( FFPE ) biopsy primary tumor metastasis use HER2 status determination . If biopsy available metastasis , HER2 test perform use metastasis . 2 . Fine needle aspiration acceptable HER 2 testing . • Women age ≥18 year • WHO performance status 0 2 Left Ventricular Ejection Fraction ( LVEF ) ≥50 % determine either ECHO MUGA Adequate organ function , evidence follow laboratory result : Neutrophils &gt; 1.5x109/L , platelet &gt; 100x109/L , hemoglobin ≥90g/L , total bilirubin ≤1.5xULN ( unless patient document Gilbert 's disease ) , AST ≤3xULN , ALT ≤3xULN , AP ≤2.5xULN ( except patient bone metastasis : AP ≤5xULN ) , creatinine ≤1.5xULN Exclusion criterion firstline therapy • Prior chemotherapy inoperable locally advanced metastatic breast cancer Note : Prior neoadjuvant/adjuvant chemotherapy allow dos anthracyclines exceed 720mg/m2 240mg/m2 epirubicin doxorubicin , respectively . Reexposure paclitaxel permit , last dose taxane give least 1 year randomization . Reexposure vinorelbine permit , last dose vinorelbine give least 1 year randomization . Prior antiHER2 treatment metastatic inoperable breast cancer Note : Prior neoadjuvant/adjuvant antiHER2 treatment trastuzumab and/or lapatinib allow . • More one endocrine treatment line metastatic inoperable breast cancer exceed duration 1 month Note : 1 . Adjuvant endocrine treatment count one line . 2 . Patients progress endocrine treatment : specific endocrine treatment must stop least 2 week prior randomization . • Prior treatment pertuzumab and/or TDM1 • Known leptomeningeal CNS metastases Note : A brain MRI CT scan mandatory case clinical suspicion CNS metastases . • Single bone metastasis treat radiotherapy ( bone metastasis tumor lesion ) Inclusion criterion secondline therapy • At least one dose trial therapy firstline treatment phase trial • • Proven disease progression firstline therapy radiotherapy bone metastasis Notes : First new parenchymal CNS metastases count progression require initiation second line trial treatment . Radiotherapy single area pain control allow count PD . • Adequate organ function , evidence follow laboratory result : Neutrophils &gt; 1.5x109/L , platelet &gt; 100x109/L , hemoglobin ≥90g/L , total bilirubin ≤1.5xULN ( unless patient document Gilbert 's disease ) , AST ≤3xULN , AP ≤2.5xULN ( except patient bone metastasis : AP ≤5xULN ) , creatinine ≤1.5ULN • LVEF ≥50 % determine either ECHO MUGA • QoL questionnaire complete . Exclusion criterion secondline therapy • Termination firstline therapy trastuzumab/pertuzumab due unacceptable toxicity without objective evidence disease progression • CNS metastasis untreated , symptomatic , require therapy control symptom , well history radiation , surgery , therapy , include steroid , control symptom CNS metastasis within 2 month ( 60 day ) registration • Peripheral neuropathy CTCAE grade ≥3 Interstitial lung disease ( ILD ) pneumonitis grade ≥3 Any adverse event recover CTCAE grade ≤1 ( except alopecia )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>HER2-positive</keyword>
	<keyword>Metastases</keyword>
</DOC>